Implant could replace daily shots for obesity and diabetes

NCT ID NCT05670379

Completed Disease control Sponsor: Vivani Medical, Inc Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This early study tested a small implant placed under the skin that steadily releases a drug called exenatide, similar to popular weight-loss and diabetes medications. The goal was to check safety and how the drug behaves in the body. Twenty-four overweight but otherwise healthy adults took part, and the implant was compared to standard injections.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: exenatide implant (a drug-device combination that releases a GLP-1 receptor agonist under the skin)
What this could lead to: If successful, this implant could offer a long-lasting, convenient way to manage weight and blood sugar without daily injections.
What could go wrong: This is a very early Phase 1 trial with only 24 people, so safety and effectiveness are not yet proven. The implant may cause side effects or fail to work as hoped.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OVERWEIGHT AND OBESITY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Obesity obesity disorder Overweight type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

OVERWEIGHT AND OBESITY TYPE2DIABETES

Contacts and locations

Locations

CMax

Adelaide, Australia

More trials for these conditions

Other studies related to the condition(s) this trial covers.